Skip to main content

Table 4 Logistic regression analyses of risk factors for failure to achieve therapeutic target within 6 months

From: Deleterious role of hepatitis B virus infection in therapeutic response among patients with rheumatoid arthritis in a clinical practice setting: a case-control study

 

OR

95% CI

p valuea

Univariate analyses

 Female

1.235

(0.367–4.155)

0.734

 Age

1.012

(0.979–1.045)

0.488

 Disease duration

1.000

(0.994–1.007)

0.969

 CHB status

3.077

(1.349–7.017)

0.008

 TJC28

1.059

0.986–1.137

0.115

 SJC28

1.035

0.951–1.127

0.421

 Pain VAS

1.096

0.897–1.338

0.369

 PtGA

1.192

0.977–1.455

0.083

 PrGA

1.142

0.920–1.418

0.230

 HAQ

1.318

0.880–1.975

0.180

 CRP

1.004

(0.988–1.020)

0.616

 ESR

1.000

(0.987–1.021)

0.949

 RF positivity

1.637

(0.557–4.811)

0.371

 ACPA positivity

0.452

(0.195–1.043)

0.063

 DAS28-CRP

1.394

(0.936–2.077)

0.102

 MMP-3

1.000

(0.999–1.002)

0.751

 mTSS

1.010

(0.995–1.024)

0.195

 Treatment-naïveb

0.300

(0.102–0.881)

0.029

 GCs

1.178

(0.465–2.989)

0.729

 MTX

0.266

(0.099–0.716)

0.009

 LEF

0.468

(0.206–1.060)

0.069

 SSZ

1.350

(0.401–4.543)

0.628

 HCQ

2.064

(0.893–4.768)

0.090

 CysA

2.850

(0.847–9.591)

0.091

 Iguratimod

2.032

(0.604–6.837)

0.252

 Biologic agents

0.555

(0.189–1.631)

0.285

 MTX combined with SSZ and HCQ

1.175

(0.275–5.009)

0.828

 MTX combined with LEF

0.365

(0.155–0.861)

0.021

 Six-month cumulative dose of GCsc

1.000

(1.000–1.001)

0.340

 Six-month cumulative dose of MTX

0.997

(0.993–1.000)

0.049

 Six-month cumulative dose of LEFd

1.000

(0.999–1.000)

0.113

 Six-month cumulative dose of SSZ

1.000

(0.995–1.005)

0.890

 Six-month cumulative dose of HCQ

1.008

(0.994–1.022)

0.245

 Six-month cumulative dose of CysAe

1.000

(1.000–1.000)

0.023

 Six-month cumulative dose of iguratimodf

1.000

(1.000–1.000)

0.259

 Six-month cumulative dose of tocilizumabg

1.000

(0.999–1.000)

0.337

 Six-month cumulative dose of Yi Sai Pu

1.001

(0.999–1.004)

0.322

 Six-month cumulative dose of infliximab

0.997

(0.986–1.009)

0.659

Bivariate models

 CHB status adjusted for treatment-naïve status

2.844

(1.245–6.498)

0.013

 CHB status adjusted for MTX

2.722

(1.177–6.298)

0.019

 CHB status adjusted for the regimen of MTX combined with LEF

3.077

(1.349–7.017)

0.008

 CHB status adjusted for 6-month cumulative dose of MTX

3.077

(1.349–7.017)

0.008

 CHB status adjusted for 6-month cumulative dose of CysA

3.077

(1.349–7.017)

0.008

Multivariate models

 CHB status adjusted for treatment-naïve status, MTX therapy, the regimen of MTX combined with LEF, and 6-month cumulative dose of CysA

2.617

(1.140–6.007)

0.023

 CHB status adjusted for treatment-naïve status, 6-month cumulative dose of MTX, the regimen of MTX combined with LEF, and 6-month cumulative dose of CysA

2.844

(1.245–6.498)

0.013

  1. ACPA anti-cyclic citrullinated peptide antibody, CHB chronic hepatitis B (HBV) infection, CI confidence interval, CRP C-reactive protein, CysA cyclosporin A, DAS28 Disease Activity Score 28-joint assessment, ESR erythrocyte sedimentation rate, GCs glucocorticosteroids, HAQ Stanford Health Assessment Questionnaire, HCQ hydroxychloroquine, LEF leflunomide, mTSS modified total Sharp score, MTX methotrexate, OR odds ratio, Pain VAS pain visual analogue scale, PrGA provider global assessment of disease activity, PtGA patient global assessment of disease activity, RF rheumatoid factor, SJC28 28-joint swollen joint count, SSZ sulfasalazine, TJC28 28-joint tender joint count
  2. aCalculated using conditional logistic regression analysis: univariate logistic regression analysis was performed on variables, including baseline characteristics, CHB status, and rheumatoid arthritis medications after enrollment (including categories of medications, 6-month cumulative doses of medications, and different regimens of combined therapies); bivariate analysis was performed by adjusting for the significant univariate factors individually; due to the multicollinearity between MTX therapy and 6-month cumulative dose of MTX, two multivariate models (MTX therapy model and 6-month cumulative dose of MTX model) were set up respectively by adjusting for all significant univariate factors: bold p values are significant
  3. bWithout glucocorticosteroid or DMARD therapy for 6 months before enrollment
  4. cSix-month cumulative dose of GCs: OR 1.000220, 95% CI 0.999768–1.000671; p = 0.340
  5. dSix-month cumulative dose of LEF: OR 0.999738, 95% CI 0.999414–1.000062; p = 0.113
  6. eSix-month cumulative dose of CysA: OR 1.000077, 95% CI 1.000011–1.000143; p = 0.023
  7. fSix-month cumulative dose of iguratimod: OR 1.000080, 95% CI 0.999941–1.000218; p = 0.259
  8. gSix-month cumulative dose of tocilizumab: OR 0.999656, 95% CI 0.998954–1.000358; p = 0.337
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us